Trial Profile
A Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 16 Oct 2015 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 23 Apr 2014 New trial record